* Resmed Inc is expected to show a rise in quarterly revenue when it reports results on April 25 for the period ending March 31 2024
* The San Diego California-based company is expected to report a 4.5% increase in revenue to $1.167 billion from $1.12 billion a year ago, according to the mean estimate from 12 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Resmed Inc is for earnings of $1.91 per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had risen by about 0.1% in the last three months.
* Wall Street's median 12-month price target for Resmed Inc is $206.00, above its last closing price of $180.35.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 1.80 1.80 1.88 Beat 4.7
Sep. 30 2023 1.61 1.62 1.64 Beat 1.4
Jun. 30 2023 1.69 1.69 1.60 Missed -5.4
Mar. 31 2023 1.59 1.59 1.68 Beat 5.9
Dec. 1.63 1.62 1.66 Beat 2.6
31 2022
Sep. 30 2022 1.52 1.52 1.51 Missed -0.4
Jun. 30 2022 1.45 1.45 1.49 Beat 2.7
Mar. 31 2022 1.42 1.42 1.32 Missed -7.2
This summary was machine generated April 23 at 20:12 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments